Basit öğe kaydını göster

dc.contributor.authorDALGIÇ, BUKET
dc.contributor.authorCokugras, Haluk
dc.contributor.authorYÜCE, AYSEL
dc.contributor.authorŞEKEREL, BÜLENT ENİS
dc.contributor.authorCullu-Cokugras, Fugen
dc.contributor.authorKansu, Aydan
dc.date.accessioned2021-03-06T09:09:27Z
dc.date.available2021-03-06T09:09:27Z
dc.date.issued2016
dc.identifier.citationKansu A., YÜCE A., DALGIÇ B., ŞEKEREL B. E. , Cullu-Cokugras F., Cokugras H., "Consensus statement on diagnosis, treatment and follow-up of cow's milk protein allergy among infants and children in Turkey", TURKISH JOURNAL OF PEDIATRICS, cilt.58, ss.1-11, 2016
dc.identifier.issn0041-4301
dc.identifier.otherav_e45b6634-9b56-4ff1-a9ba-a90e2a0614ef
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/150268
dc.identifier.urihttps://doi.org/10.24953/turkjped.2016.01.001
dc.description.abstractThe present paper aims to provide experts' consensus on diagnosis and management of cow's milk protein allergy (CMPA) among infants and children in Turkey, based on review of available evidence-based guidelines, publications and experts' clinical experience. The experts agreed that CMPA diagnosis should be based on symptomatic evaluation and diagnostic elimination diet as followed by implementation of an open challenge test after disappearance of symptoms and confirmation of CMPA diagnosis in re-appearance of symptoms. For breastfed infants, differential diagnosis involves withdrawal of cow's milk-containing products from the mother's diet, while calcium supplements and appropriate dietary advice are given to mothers to prevent nutritional deficiency. For infants not breastfed exclusively, cow's milk-based formula and any complementary food containing cow's milk protein (CMP) should be avoided. The first line treatment should be extensively hydrolyzed formula (eHF) with use of amino acid-based formula (AAF) in severe cases such as anaphylaxis, enteropathy, eosinophilic esophagitis and food protein induced enterocolitis along with cases of multiple system involvement, multiple food allergies and intolerance to eHF. Introduction of supplementary foods should not be delayed in CMPA, while should be made one by one in small amounts and only after the infant is at least 17 weeks of age. Infants who are at-risk can be identified by family history of atopic disease. Exclusive breastfeeding for 4-6 months (17-27 weeks) is recommended as the best method of infant allergy prevention. There is no evidence that modifying the mother's diet during pregnancy and/or breast-feeding and delaying solid or even potentially allergic foods beyond 4-6 months in infants may be protective against allergy among at-risk infants. When exclusive breastfeeding is not possible, at-risk infants should get a partially or extensively hydrolyzed formula (pHF or eHF) to prevent allergy until risk evaluation by a health professional. In conclusion, the present consensus statement provides recommendations regarding diagnosis, prevention and management of CMPA in infants and children in Turkey, and thus expected to guide physicians to optimize their approach to CMPA and decrease burden of the disease on infants and their caregivers.
dc.language.isoeng
dc.subjectÇocuk Sağlığı ve Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectPEDİATRİ
dc.titleConsensus statement on diagnosis, treatment and follow-up of cow's milk protein allergy among infants and children in Turkey
dc.typeMakale
dc.relation.journalTURKISH JOURNAL OF PEDIATRICS
dc.contributor.departmentAnkara Üniversitesi , ,
dc.identifier.volume58
dc.identifier.issue1
dc.identifier.startpage1
dc.identifier.endpage11
dc.contributor.firstauthorID228875


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster